Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old with High-Risk Conditions.

Matthew Davis,William Towner, Elliot Dehaan,Qin Jiang, Wen Li, Farah Rahman,Michael Patton, Hayley Wyper, Maria Maddalena Lino,Uzma N. Sarwar, Zaynah Majid-Mahomed, Saumil Mehta, William Howitt,Kevin Cannon, Elena Kalinina,David Cooper,Kena A. Swanson,Annaliesa S. Anderson,Alejandra Gurtman,Iona Munjal, Natalia Castillo MONeT Study Team

CLINICAL INFECTIOUS DISEASES（2024）

Cited 0|Views0

Key words

RSV,RSVpreF,vaccine,immunogenicity,safety

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined